12:00 AM
Jan 01, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/29 cls
Advancis (AVNC) Merriman Curhan Ford Brian McCarthy New Buy 10% $3.91
McCarthy said FDA approval of Amoxicillin Pulsys could drive the stock to the $12-$15 range. Last month, AVNC submitted an NDA for once-daily use of the pulsatile-release formulation of amoxicillin to treat adolescents and adults with pharyngitis/tonsillitis (strep throat). McCarthy expects approval in 4Q07.
Avalon (AVRX) Rodman Ren Benjamin New Market outperform 5% $3.90
Benjamin set a $10 target. He said lead candidate AVN944 is likely to start Phase II testing in cancer by mid-2007. AVRX holds exclusive worldwide rights to the inosine monophosphate dehydrogenase (IMPDH) inhibitor from Vertex (VRTX). Benjamim also said AVRX's AvalonRx platform is likely to attract additional pharma partnerships in the coming year.
Dynavax (DVAX) Merriman Curhan Ford Brian McCarthy New Buy 1% $9.18

Read the full 887 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >